Journal
MOLECULAR PSYCHIATRY
Volume 14, Issue 8, Pages 764-773Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/mp.2008.119
Keywords
depression; neurogenesis; neuroplasticity; antidepressant; NCAM; synapsin 1
Funding
- National Cancer Institute [N02-CB-07008]
- Sanofi-Synthelabo [SSR 149415]
- Pfizer [CP 156,526]
- Portuguese Foundation for Science and Technology (FCT) [PTDC/SAU-NEU/72699/2006]
- Fundação para a Ciência e a Tecnologia [PTDC/SAU-NEU/72699/2006] Funding Source: FCT
Ask authors/readers for more resources
The mechanisms underlying the initiation/onset of, and the recovery from, depression are still largely unknown; views that neurogenesis in the hippocampus may be important for the pathogenesis and amelioration of depressive symptoms have gained currency over the years although the original evidence has been challenged. In this study, an unpredictable chronic mild stress protocol was used to induce a depressive-like phenotype in rats. In the last 2 weeks of stress exposure, animals were treated with the antidepressants fluoxetine, imipramine, CP 156,526 or SSR 1494515, alone or combined with methylazoxymethanol, a cytostatic agent used to arrest neurogenesis. We found that antidepressants retain their therapeutic efficacy in reducing both measured indices of depression-like behavior (learned helplessness and anhedonia), even when neurogenesis is blocked. Instead, our experiments suggest re-establishment of neuronal plasticity (dendritic remodeling and synaptic contacts) in the hippocampus and prefrontal cortex, rather than neurogenesis, as the basis for the restoration of behavioral homeostasis by antidepressants. Molecular Psychiatry (2009) 14, 764-773; doi:10.1038/mp.2008.119; published online 4 November 2008
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available